Lower Limb Reconstruction, Robert Jones Agnes Hunt Hospital, Gobowen, UK.
The Royal Orthopaedic Hospital, Birmingham, UK.
Bone Joint J. 2024 Jun 1;106-B(6):540-547. doi: 10.1302/0301-620X.106B6.BJJ-2023-1064.R1.
The Birmingham Hip Resurfacing (BHR) was introduced in 1997 to address the needs of young active patients using a historically proven large-diameter metal-on-metal (MoM) bearing. A single designer surgeon's consecutive series of 130 patients (144 hips) was previously reported at five and ten years, reporting three and ten failures, respectively. The aim of this study was to extend the follow-up of this original cohort at 25 years.
The study extends the reporting on the first consecutive 144 resurfacing procedures in 130 patients for all indications. All operations were undertaken between August 1997 and May 1998. The mean age at operation was 52.1 years (SD 9.93; 17 to 76), and included 37 female patients (28.5%). Failure was defined as revision of either component for any reason. Kaplan-Meier survival analysis was performed. Routine follow-up with serum metal ion levels, radiographs, and Oxford Hip Scores (OHSs) was undertaken.
Overall implant survival was 83.50% (95% confidence interval (CI) 0.79 to 0.90) at 25 years, and the number at risk was 79. Survival in male patients at 25 years was 89.5% (95% CI 0.83 to 0.96) compared to 66.9% for female patients (95% CI 0.51 to 0.83). Ten additional failures occurred in the period of ten to 25 years. These involved an adverse reaction to metal debris in four patients, a periprosthetic femoral neck fracture affecting five patients, and aseptic loosening in one patient. The median chromium levels were 49.50 nmol/l (interquartile range (IQR) 34 to 70), and the median cobalt serum levels were 42 nmol/l (IQR 24.50 to 71.25). The median OHS at last follow-up was 35 (IQR 10 to 48). During the 25-year study period, 29 patients died. Patient survival at 25 years was 75.10% (95% CI 0.67 to 0.83).
This study demonstrates that MoM hip resurfacing using the BHR provides a durable alternative to total hip arthroplasty (THA), particularly in younger male patients with osteoarthritis wishing to maintain a high level of function. These results compare favourably to the best results for THAs.
Birmingham Hip Resurfacing(BHR)于 1997 年推出,旨在满足年轻活跃患者的需求,使用历史上经过验证的大直径金属对金属(MoM)轴承。先前曾报道过一位单一设计师外科医生的连续 130 例患者(144 髋)的系列研究,分别在 5 年和 10 年时报告了 3 例和 10 例失败。本研究的目的是将该原始队列的随访时间延长至 25 年。
本研究扩展了对 130 例患者的 144 例髋关节表面置换术的最初连续报告,适应证为所有适应证。所有手术均于 1997 年 8 月至 1998 年 5 月间进行。手术时的平均年龄为 52.1 岁(标准差 9.93;17 至 76 岁),包括 37 例女性患者(28.5%)。失败的定义为任何原因的任何组件的翻修。进行了 Kaplan-Meier 生存分析。进行了常规的血清金属离子水平、影像学和牛津髋关节评分(OHS)随访。
25 年时总体植入物存活率为 83.50%(95%置信区间(CI)0.79 至 0.90),风险人数为 79。25 年时男性患者的生存率为 89.5%(95%CI 0.83 至 0.96),而女性患者为 66.9%(95%CI 0.51 至 0.83)。在 10 年至 25 年期间又发生了 10 例额外的失败。这些涉及四名患者的金属碎屑不良反应、五名患者的股骨颈假体周围骨折以及一名患者的无菌性松动。中位铬水平为 49.50 nmol/L(四分位距(IQR)34 至 70),中位钴血清水平为 42 nmol/L(IQR 24.50 至 71.25)。最后一次随访时的中位数 OHS 为 35(IQR 10 至 48)。在 25 年的研究期间,有 29 名患者死亡。25 年时患者生存率为 75.10%(95%CI 0.67 至 0.83)。
本研究表明,使用 Birmingham Hip Resurfacing(BHR)的 MoM 髋关节置换术为全髋关节置换术(THA)提供了一种持久的替代方法,尤其是在希望保持高水平功能的年轻男性骨关节炎患者中。这些结果与 THA 的最佳结果相当。